Thyrocare TechnologiesNSE:THYROCARE -1.87%89 FCF Yield % is 2.22 as of Jul. 07, 2026, which is 204% above its 10-year median of 0.73. GuruFocus rates NSE:THYROCARE with a GF Score™ of 89/100 and a GF Value™ of ₹393.97 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 66.98% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Thyrocare Technologies's FCF Yield % or its related term are showing as below:
NSE:THYROCARE'
s FCF Yield % Range Over the Past 10 Years
Min: 0.25 Med: 0.73 Max: 2.22
Current: 2.22
During the past 13 years, the highest FCF Yield % of Thyrocare Technologies was 2.22%. The lowest was 0.25%. And the median was 0.73%.
NSE:THYROCARE's FCF Yield % is ranked better than 66.98% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.4
vs NSE:THYROCARE: 2.22
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thyrocare Technologies FCF Yield % Related Terms
Thyrocare Technologies FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a FCF Yield % of 2.22 as of Jul. 07, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Thyrocare Technologies and its competitors. This is 204% above median its historical median of 0.73. Over the past decade, Thyrocare Technologies' FCF Yield % has ranged from 0.25 to 2.22. According to the industry distribution chart, Thyrocare Technologies ranks #71 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 33%.
Is Thyrocare Technologies' FCF Yield % too high?
Thyrocare Technologies' current FCF Yield % of 2.22 is 204% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 2.22. Based on the distribution chart, Thyrocare Technologies ranks #71 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thyrocare Technologies has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #71 out of 215 companies for FCF Yield %. This puts Thyrocare Technologies in the upper half of its industry. Historically, Thyrocare Technologies' own FCF Yield % has ranged from 0.25 to 2.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current FCF Yield % is 2.22, which is 204% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹393.97, compared to a current price of ₹545.20 — trading 38.4% above its estimated fair value. The current FCF Yield % is 2.22, which is 204% above median its 10-year median of 0.73. Thyrocare Technologies' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current FCF Yield % is 2.22 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹545.20 is trading 38.4% above its estimated GF Value™ of ₹393.97.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
FCF Yield %: 2.22 (204% above median its 10-year median of 0.73)
GF Value™: ₹393.97 vs. price of ₹545.20 (38.4% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
89GF Score
Get the complete analysis for NSE:THYROCARE
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
